COX-2 inhibitors and the development of unstable angina and myocardial infarction
COX-2 inhibitors and the development of unstable angina and myocardial infarction
批准号:
nhmrc : 252469
负责人:
A/Pr Julia Lowe
金额:
$11.43万
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2003
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2003-01-01 至 2005-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Anti-inflammatory drugs (sometimes called NSAIDs) are widely used in the treatment of arthritis and also as general purpose pain killers. Up to 10 million prescriptions are written each year for these drugs in Australia. Some of the older versions of these drugs like ibuprofen (eg Brufen) and naproxen (trade name Naproxen) cause side effects which can be serious. Damage to the stomach is a particular problem and this can lead to serious bleeding or perforation of ulcers. Less well recognized are the adverse effects of these drugs on the heart and the kidneys. The older fashioned members of this class of drug are rapidly being replaced by newer agents known as COX-2 inhibitors. Popular examples in Australia are celecoxib (trade name Celebrex) and rofecoxib (trade name Vioxx). These drugs are heavily promoted as being safer than the older NSAIDs. In the case of the stomach, this claim seems to be correct. However, the effects of the new COX-2 inhibitors on the circulation have not been fully assessed. Recently, claims have been made that these drugs may increase the risk of heart attacks. If this were true, it would be an effect that was unique to COX-2 inhibitors as it has not been reported with the older NSAIDs. We plan to carry out a 3 year study in Newcastle hospitals in which we compare the use of COX-2 inhibitors in a group of patients admitted to hospital with a heart attack or unstable angina with that of a control group of patients who were admitted to hospital around the same time, but not for heart problems. We are interested in whether COX-2 inhibitors are associated with an increased risk of heart attacks and whether use of small doses of aspirin protects against this effect. Depending on the results we may be able to improve the safety of these drugs in patients at risk of heart attacks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Implementation and evaluation of a Systems Navigation Model of Transition and Care for Non-Metropolitan Young Adults with Type 1 Diabetes: Youth OutReach for Diabetes (YOuR-Diabetes) Cluster-Randomised Controlled Trial in Hunter New England
-
批准号:nhmrc : 1016625
-
项目类别:Partnerships
-
资助金额:$51.33万
-
财政年份:2011
-
负责人:A/Pr Julia Lowe
-
依托单位:
COX-2 INHIBITORS AS A CAUSE OF HEART AND RENAL FAILURE
-
批准号:nhmrc : 209839
-
项目类别:NHMRC Project Grants
-
资助金额:$18.11万
-
财政年份:2002
-
负责人:A/Pr Julia Lowe
-
依托单位:
国内基金
海外基金
登录
查看更多内容
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
-
批准号:82371317
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:万杰清
-
依托单位:
多羟基吡咯里西啶及其3-取代衍生物的合成及糖苷酶抑制活性的生物学评价
-
批准号:81060254
-
项目类别:地区科学基金项目
-
资助金额:28.0万元
-
批准年份:2010
-
负责人:李洪庆
-
依托单位:
2-取代的七元氮杂糖及其缩环产物六元氮杂糖的合成和糖苷酶抑制活性的生物学评价
-
批准号:30860341
-
项目类别:地区科学基金项目
-
资助金额:23.0万元
-
批准年份:2008
-
负责人:李洪庆
-
依托单位:
基于penicillide结构的类天然产物合成及其胆固醇酯转运蛋白抑制的研究
-
批准号:20872019
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2008
-
负责人:雷新胜
-
依托单位:
昆虫酚氧化酶抑制剂的抑制机理及其构效关系研究
-
批准号:30571237
-
项目类别:面上项目
-
资助金额:28.0万元
-
批准年份:2005
-
负责人:罗万春
-
依托单位:
建立甲状腺髓样癌的细胞和动物模型以及研究RET原癌基因突变的致病机制
-
批准号:30370666
-
项目类别:面上项目
-
资助金额:20.0万元
-
批准年份:2003
-
负责人:赵咏桔
-
依托单位: